H.C. Wainwright Raises the PT on ​CorMedix Inc. (CRMD), Keeps a Buy

Core Insights - CorMedix Inc. (NASDAQ:CRMD) is recognized as a fast-growing small-cap stock, with analysts recommending it as a buy following a strong earnings report for fiscal Q3 2025 [1][2] - The company reported a significant revenue increase of 810.21% year-over-year, reaching $104.28 million, which exceeded estimates by $18.25 million [2] - Earnings per share (EPS) for the quarter was $1.26, surpassing consensus estimates by $0.63 [2] Financial Performance - The revenue growth was primarily driven by higher utilization of DefenCath among outpatient dialysis customers, contributing $88.8 million to net revenue [2] - CorMedix raised its full-year pro forma net revenue guidance to a range of $390 to $410 million and fourth-quarter guidance to $115 to $135 million [3] Strategic Developments - The recent acquisition of Melinta has diversified CorMedix's business and contributed to its robust financial results [4] - The company has a promising pipeline with significant growth catalysts, including anticipated results from the Rezzayo study and TPN Phase 3 data for DefenCath [4] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products aimed at preventing and treating life-threatening infectious and inflammatory diseases [5]